TABLE 1.

Demographic information of 45 COVID‐19 patients who received monoclonal antibodies at congregate living facilities

	Patients (%), n = 45
Age	77.8 (52–99)
Gender
Male	19 (42.2%)
Female	26 (57.8%)
Risk factors
Aged >65	40 (88.9%)
Cardiovascular disease	23 (51.1%)
Diabetes mellitus	22 (48.9%)
BMI >35	12 (26.7%)
Chronic lung disease	9 (20.0%)
Chronic kidney disease	4 (8.9%)
Immunocompromised status	2 (4.4%)
Monoclonal antibody preparation
Bamlanivimab	6 (13.3%)
Casirivimab/imdevimab	39 (86.7%)